2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Withdrawn
1
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Other hematologic neoplasm
2
Conditions
Leukemia, Myeloid, Acute
5
Leukemia
5
Mycoses
4
Infections
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Neutropenia
3
Neuroblastoma
3
Burkitt Lymphoma
3
Wilms Tumor
2
Waldenstrom Macroglobulinemia
2
Thrombocythemia, Essential
2
Testicular Neoplasms
2
Sezary Syndrome
2
Primary Myelofibrosis
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Polycythemia Vera
2
Neoplasms
2
Mycosis Fungoides
2
Multiple Myeloma
2
Monoclonal Gammopathy of Undetermined Significance
2
Lymphoma, T-Cell, Cutaneous
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Mantle-Cell
2
Lymphoma, Large-Cell, Immunoblastic
2
Lymphoma, Large-Cell, Anaplastic
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, Follicular
2
Lymphoma, B-Cell, Marginal Zone
2
Leukemia, Prolymphocytic
2
Leukemia, Myelomonocytic, Chronic
2
Interventions
Caspofungin
2
olorofim
1
liposomal amphotericin B
1
Voriconazole
1
Blood Specimen Collection
1
Amphotericin B
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Invasive Pulmonary Aspergillosis
×
Caspofungin
×
Clear all
NCT02856178
2018-02-15
SAFEGUARD
F2G Biotech GmbH
Phase 1/2
Withdrawn
NCT00501098
2009-09-22
PROFIL-C
Northern Italy Leukemia Group
Phase 2
Completed
100 enrolled